These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
Commission File Number
|
|
|
|
Exact Name of Registrant as Specified in its Charter, Address of Principal Executive Offices and Telephone Number
|
|
State or other jurisdiction of incorporation or organization
|
|
I.R.S. Employer Identification No.
|
|
001-35832
|
|
|
|
Science Applications
International Corporation
|
|
Delaware
|
|
46-1932921
|
|
|
|
|
|
12010 Sunset Hills Road, Reston, VA 20190
|
|
|
|
|
|
|
|
|
|
703-676-4300
|
|
|
|
|
|
|
|
Title of each class
|
|
Name of each exchange on which registered
|
|
Science Applications International Corporation
Common Stock, Par Value $.0001 Per Share
|
|
New York Stock Exchange
|
|
|
|
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
|
Yes
x
|
No ☐
|
|
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
|
Yes
☐
|
No
x
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
|
Yes
x
|
No
☐
|
|
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
|
Yes
x
|
No
☐
|
|
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
|
x
|
|
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
Large accelerated filer
|
x
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
☐
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
|
|
Yes
☐
|
|
No
x
|
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
FORM 10-K
TABLE OF CONTENTS
|
|
|
|
Page
|
|
Part I
|
|
|
|
|
|
|
|
Item 1.
|
||
|
Item 1A.
|
||
|
Item 1B.
|
||
|
Item 2.
|
||
|
Item 3.
|
||
|
Item 4.
|
||
|
|
|
|
|
Part II
|
|
|
|
|
|
|
|
Item 5.
|
||
|
Item 6.
|
||
|
Item 7.
|
||
|
Item 7A.
|
||
|
Item 8.
|
||
|
Item 9.
|
||
|
Item 9A.
|
||
|
Item 9B.
|
||
|
|
|
|
|
Part III
|
|
|
|
|
|
|
|
Item 10.
|
||
|
Item 11.
|
||
|
Item 12.
|
||
|
Item 13.
|
||
|
Item 14.
|
||
|
|
|
|
|
Part IV
|
|
|
|
|
|
|
|
Item 15.
|
||
|
Item 16.
|
||
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|||||||
|
|
February 2, 2018
|
|
|
February 3, 2017
|
|
|
January 29, 2016
|
|
|
U.S. Army
|
30
|
%
|
|
28
|
%
|
|
29
|
%
|
|
U.S. Navy
|
13
|
%
|
|
13
|
%
|
|
16
|
%
|
|
Other DoD
|
19
|
%
|
|
17
|
%
|
|
21
|
%
|
|
Other federal government
|
36
|
%
|
|
40
|
%
|
|
31
|
%
|
|
Total U.S. government
|
98
|
%
|
|
98
|
%
|
|
97
|
%
|
|
Other
|
2
|
%
|
|
2
|
%
|
|
3
|
%
|
|
Total
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
•
|
Cost-reimbursement contracts provide for reimbursement of our direct contract costs and allocable indirect costs, plus a fee (contract profit). This type of contract is generally used when uncertainties involved in contract performance do not permit costs to be estimated with sufficient accuracy to use a fixed-price contract. Cost-reimbursement contracts usually subject us to lower risk and generally require us to use our best efforts to accomplish the scope of the work within a specified time and amount of costs.
|
|
•
|
Time-and-materials (T&M) contracts typically provide for negotiated fixed hourly rates for specified categories of direct labor plus reimbursement of other direct costs. This type of contract is generally used when there is uncertainty of the extent or duration of the work to be performed by the contractor at the time of contract award or it is not possible to anticipate costs with any reasonable degree of confidence. On T&M contracts, we assume the risk of providing appropriately qualified staff to perform these contracts at the hourly rates set forth in the contracts over their period of performance.
|
|
•
|
Firm-fixed price (FFP) contracts provide for a predetermined price for specific solutions. These contracts offer us potential increased profits if we can complete the work at lower costs than planned. While FFP contracts allow us to benefit from cost savings, these contracts also increase our exposure to reduced profits or losses from increased or unexpected costs.
|
|
•
|
the engineering and technical services divisions of large defense contractors that provide IT services in addition to other hardware systems and products, which include companies such as General Dynamics Corporation, Northrop Grumman Corporation, L-3 Communications Corporation and Raytheon Company;
|
|
•
|
contractors focused principally on technical and IT services, such as Booz Allen Hamilton Inc., Engility Holdings, Inc., CACI International, Inc., Leidos Holdings, Inc., ManTech International Corporation, Serco Group plc, Vencore and CSRA Inc.;
|
|
•
|
diversified commercial providers that also provide U.S. government IT services, such as Accenture plc, HP Enterprise Services, International Business Machines Corporation and Unisys Corporation; and
|
|
•
|
contractors providing supply chain management and other logistics services, such as Agility Logistics Corporation
|
|
•
|
we may not retain key employees (including those with needed security clearances), customers and business partners of an acquired business in the future;
|
|
•
|
we may fail to successfully integrate acquired businesses, such as failing to successfully implement IT and other control systems relating to the operations of any acquired business;
|
|
•
|
we may not generate sufficient earnings to meet the required Leverage Ratio under the Credit Facility, which would give lenders the right to, among other things, foreclose on our assets;
|
|
•
|
acquisitions normally require a significant investment of time and resources, which may disrupt our business and distract our management from other important responsibilities;
|
|
•
|
we may not be able to accurately estimate the financial effect of any acquisitions and investments on our business and we may not realize anticipated revenue opportunities, cost savings, or other synergies or benefits, or acquisitions may not result in improved operating performance; and
|
|
•
|
we may assume known as well as unknown material liabilities, legal or regulatory risks that were not identified as part of our due diligence or for which we are unable to receive a purchase price adjustment or reimbursement through indemnification;
|
|
|
Fiscal 2018
|
|
Fiscal 2017
|
|
First Quarter
|
$70.10 to $89.24
|
|
$40.50 to $54.17
|
|
Second Quarter
|
$69.10 to $81.44
|
|
$51.45 to $62.09
|
|
Third Quarter
|
$61.06 to $74.85
|
|
$60.52 to $70.62
|
|
Fourth Quarter
|
$67.89 to $79.97
|
|
$70.66 to $88.65
|
|
|
Fiscal 2018
|
|
Fiscal 2017
|
||||
|
First Quarter
|
$
|
0.31
|
|
|
$
|
0.31
|
|
|
Second Quarter
|
$
|
0.31
|
|
|
$
|
0.31
|
|
|
Third Quarter
|
$
|
0.31
|
|
|
$
|
0.31
|
|
|
Fourth Quarter
|
$
|
0.31
|
|
|
$
|
0.31
|
|
|
Period
(1)
|
Total Number of Shares (or Units) Purchased
(2)
|
|
|
Average Price Paid per Share (or Unit)
|
|
|
Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs
|
|
|
Maximum Number of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
(3)
|
|
|
|
November 4, 2017 - December 8, 2017
|
204,604
|
|
|
$
|
71.25
|
|
|
204,174
|
|
|
3,004,393
|
|
|
December 9, 2017 - January 5, 2018
|
130,417
|
|
|
77.72
|
|
|
129,815
|
|
|
2,874,578
|
|
|
|
January 6, 2018 - February 2, 2018
|
145,790
|
|
|
77.79
|
|
|
144,457
|
|
|
2,730,121
|
|
|
|
Total
|
480,811
|
|
|
$
|
74.99
|
|
|
478,446
|
|
|
|
|
|
(1)
|
Date ranges represent our fiscal periods during the current quarter. Our fiscal quarters typically consist of one five-week period and two four-week periods.
|
|
(2)
|
Includes shares purchased on surrender by stockholders of previously owned shares to satisfy minimum statutory tax withholding obligations related to stock option exercises and vesting of stock awards in addition to shares purchased under our publicly announced plans or programs.
|
|
(3)
|
On December 15, 2016, the number of additional shares of our common stock that may be repurchased under our existing repurchase program previously announced in October 2013 was increased by approximately 3.3 million shares, bringing the total authorized shares to be repurchased under the program to approximately
11.8 million
shares. As of
February 2, 2018
, we have repurchased approximately
9.1 million
shares of common stock under the program.
|
|
|
Year Ended
|
||||||||||||||||||
|
|
February 2,
2018 |
|
|
February 3,
2017
(2)
|
|
|
January 29,
2016 |
|
|
January 30,
2015 |
|
|
January 31,
2014 |
|
|||||
|
|
(in millions, except per share data)
|
||||||||||||||||||
|
Consolidated and Combined Statement of Income Data:
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Total revenues
|
$
|
4,454
|
|
|
$
|
4,442
|
|
|
$
|
4,315
|
|
|
$
|
3,885
|
|
|
$
|
4,121
|
|
|
Operating income
|
256
|
|
|
263
|
|
|
227
|
|
|
240
|
|
|
183
|
|
|||||
|
Net income
|
179
|
|
|
143
|
|
|
117
|
|
|
141
|
|
|
113
|
|
|||||
|
Earnings per share
(1)
:
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Basic
|
$
|
4.13
|
|
|
$
|
3.21
|
|
|
$
|
2.55
|
|
|
$
|
3.01
|
|
|
$
|
2.33
|
|
|
Diluted
|
$
|
4.02
|
|
|
$
|
3.12
|
|
|
$
|
2.47
|
|
|
$
|
2.91
|
|
|
$
|
2.27
|
|
|
Cash dividend per share
|
$
|
1.24
|
|
|
$
|
1.24
|
|
|
$
|
1.21
|
|
|
$
|
1.12
|
|
|
$
|
0.56
|
|
|
Consolidated and Combined Balance Sheet Data:
|
February 2,
2018 |
|
|
February 3,
2017
(2)
|
|
|
January 29,
2016 |
|
|
January 30,
2015 |
|
|
January 31,
2014 |
|
|||||
|
Total assets
|
$
|
2,073
|
|
|
$
|
2,042
|
|
|
$
|
2,122
|
|
|
$
|
1,389
|
|
|
$
|
1,442
|
|
|
Long-term debt, including current portion
|
1,024
|
|
|
1,047
|
|
|
1,070
|
|
|
486
|
|
|
498
|
|
|||||
|
Other long-term liabilities and deferred income taxes
|
68
|
|
|
48
|
|
|
41
|
|
|
38
|
|
|
31
|
|
|||||
|
(1)
|
For more information on the calculation of Basic and Diluted Earnings per share see
Note 2
of the notes to the consolidated financial statements contained within this report.
|
|
(2)
|
Fiscal 2017 amounts have been restated to adjust for the impacts from the correction of fiscal 2017 revenues as described in Note 1 of the notes to the consolidated financial statements contained within this report.
|
|
|
Fiscal 2018
|
|
|
Fiscal 2017
|
|
|
Fiscal 2016
|
|
|
|
(weeks)
|
|||||||
|
First Quarter
|
13
|
|
|
14
|
|
|
13
|
|
|
Second Quarter
|
13
|
|
|
13
|
|
|
13
|
|
|
Third Quarter
|
13
|
|
|
13
|
|
|
13
|
|
|
Fourth Quarter
|
13
|
|
|
13
|
|
|
13
|
|
|
Fiscal Year
|
52
|
|
|
53
|
|
|
52
|
|
|
•
|
low single digit annual internal revenue growth percentage,
|
|
•
|
adjusted EBITDA margin expansion of 10 to 20 basis points annually, and
|
|
•
|
return of capital in excess of operating needs.
|
|
|
Year Ended
|
||||||||||||||||
|
|
February 2, 2018
|
|
|
Percent change
|
|
February 3, 2017
|
|
|
Percent change
|
|
January 29, 2016
|
|
|||||
|
|
(dollars in millions)
|
||||||||||||||||
|
Revenues
|
$
|
4,454
|
|
|
—
|
%
|
|
$
|
4,442
|
|
|
3
|
%
|
|
$
|
4,315
|
|
|
Cost of revenues
|
4,043
|
|
|
1
|
%
|
|
4,003
|
|
|
3
|
%
|
|
3,904
|
|
|||
|
As a percentage of revenues
|
90.8
|
%
|
|
|
|
90.1
|
%
|
|
|
|
90.5
|
%
|
|||||
|
Selling, general and administrative expenses
|
155
|
|
|
(12
|
)%
|
|
176
|
|
|
(4
|
)%
|
|
184
|
|
|||
|
Operating income
|
256
|
|
|
(3
|
)%
|
|
263
|
|
|
16
|
%
|
|
227
|
|
|||
|
As a percentage of revenues
|
5.7
|
%
|
|
|
|
5.9
|
%
|
|
|
|
|
5.3
|
%
|
||||
|
Net income
|
$
|
179
|
|
|
25
|
%
|
|
$
|
143
|
|
|
22
|
%
|
|
$
|
117
|
|
|
Cash flows provided by operating activities
|
$
|
217
|
|
|
(21
|
)%
|
|
$
|
273
|
|
|
21
|
%
|
|
$
|
226
|
|
|
|
Year Ended
|
||||||
|
|
February 2, 2018
|
|
|
February 3, 2017
|
|
||
|
|
(in millions)
|
||||||
|
Prior year period's revenues, as reported
|
$
|
4,442
|
|
|
$
|
4,315
|
|
|
Prior year period's revenues performed by former Parent
|
(9
|
)
|
|
(31
|
)
|
||
|
Estimated impact of 53rd week
|
(88
|
)
|
|
—
|
|
||
|
Revenues of acquired business for the pre-acquisition prior year period
|
—
|
|
|
154
|
|
||
|
Prior year period's revenues, as adjusted
|
4,345
|
|
|
4,438
|
|
||
|
Current year revenues, as reported
|
4,454
|
|
|
4,442
|
|
||
|
Revenues performed by former Parent
|
—
|
|
|
(9
|
)
|
||
|
Estimated impact of 53rd week
|
—
|
|
|
(88
|
)
|
||
|
Current year period's revenues, as adjusted
|
4,454
|
|
|
4,345
|
|
||
|
Internal revenue growth (contraction)
|
$
|
109
|
|
|
$
|
(93
|
)
|
|
Internal revenue growth (contraction) percentage
|
2.5
|
%
|
|
(2.1
|
)%
|
||
|
|
Year Ended
|
||||||||||
|
|
February 2, 2018
|
|
|
February 3, 2017
|
|
|
January 29, 2016
|
|
|||
|
|
(in millions)
|
||||||||||
|
Net income
|
$
|
179
|
|
|
$
|
143
|
|
|
$
|
117
|
|
|
Interest expense
|
44
|
|
|
52
|
|
|
44
|
|
|||
|
Interest income
|
(1
|
)
|
|
—
|
|
|
—
|
|
|||
|
Provision for income taxes
|
35
|
|
|
69
|
|
|
66
|
|
|||
|
Depreciation and amortization
|
44
|
|
|
50
|
|
|
59
|
|
|||
|
EBITDA
|
301
|
|
|
314
|
|
|
286
|
|
|||
|
EBITDA as a percentage of revenues
|
6.8
|
%
|
|
7.1
|
%
|
|
6.6
|
%
|
|||
|
Restructuring costs
|
13
|
|
|
—
|
|
|
—
|
|
|||
|
Acquisition and integration costs
|
—
|
|
|
10
|
|
|
26
|
|
|||
|
Depreciation included in restructuring costs and acquisition and integration costs
|
(1
|
)
|
|
(2
|
)
|
|
(3
|
)
|
|||
|
Adjusted EBITDA
|
$
|
313
|
|
|
$
|
322
|
|
|
$
|
309
|
|
|
Adjusted EBITDA as a percentage of revenues
|
7.0
|
%
|
|
7.2
|
%
|
|
7.2
|
%
|
|||
|
•
|
Funded Backlog.
Funded backlog for contracts with government agencies primarily represents estimated amounts of revenue to be earned in the future from contracts for which funding is appropriated less revenues previously recognized on these contracts. It does not include the unfunded portion of contracts in which funding is incrementally appropriated or authorized on a quarterly or annual basis by the U.S. government and other customers even though the contract may call for performance over a number of years. Funded backlog for contracts with non-government customers represents the estimated value on contracts, which may cover multiple future years, under which we are obligated to perform, less revenues previously recognized on these contracts.
|
|
•
|
Negotiated Unfunded Backlog.
Negotiated unfunded backlog represents estimated amounts of revenue to be earned in the future from negotiated contracts for which funding has not been appropriated or otherwise authorized and from unexercised priced contract options. Negotiated unfunded backlog does not include any estimate of future potential task orders expected to be awarded under IDIQ, GSA Schedules or other master agreement contract vehicles.
|
|
|
February 2, 2018
|
|
|
February 3, 2017
|
|
||
|
|
(in millions)
|
||||||
|
Funded backlog
|
$
|
2,012
|
|
|
$
|
1,811
|
|
|
Negotiated unfunded backlog
|
8,215
|
|
|
6,209
|
|
||
|
Total backlog
|
$
|
10,227
|
|
|
$
|
8,020
|
|
|
|
|
Year Ended
|
|||||||
|
|
|
February 2, 2018
|
|
|
February 3, 2017
|
|
|
January 29, 2016
|
|
|
Cost reimbursement
|
|
45
|
%
|
|
41
|
%
|
|
39
|
%
|
|
Time and materials (T&M)
|
|
27
|
%
|
|
30
|
%
|
|
29
|
%
|
|
Firm-fixed price (FFP)
|
|
28
|
%
|
|
29
|
%
|
|
32
|
%
|
|
Total
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
Year Ended
|
|||||||
|
|
|
February 2, 2018
|
|
|
February 3, 2017
|
|
|
January 29, 2016
|
|
|
|
|
(as a % of total cost of revenues)
|
|||||||
|
Labor-related cost of revenues
|
|
47
|
%
|
|
48
|
%
|
|
46
|
%
|
|
Subcontractor-related cost of revenues
|
|
33
|
%
|
|
34
|
%
|
|
34
|
%
|
|
Supply chain materials-related cost of revenues
|
|
13
|
%
|
|
12
|
%
|
|
14
|
%
|
|
Other materials-related cost of revenues
|
|
7
|
%
|
|
6
|
%
|
|
6
|
%
|
|
|
Year Ended
|
||||||||||
|
|
February 2, 2018
|
|
|
February 3, 2017
|
|
|
January 29, 2016
|
|
|||
|
|
(in millions)
|
||||||||||
|
Net cash provided by operating activities
|
$
|
217
|
|
|
$
|
273
|
|
|
$
|
226
|
|
|
Net cash used in investing activities
|
(22
|
)
|
|
(17
|
)
|
|
(784
|
)
|
|||
|
Net cash (used in) provided by financing activities
|
(261
|
)
|
|
(247
|
)
|
|
466
|
|
|||
|
Total (decrease) increase in cash, cash equivalents and restricted cash
|
$
|
(66
|
)
|
|
$
|
9
|
|
|
$
|
(92
|
)
|
|
|
Payments Due by Fiscal Year
|
||||||||||||||||||
|
|
Total
|
|
|
2019
|
|
|
2020-2021
|
|
|
2022-2023
|
|
|
2024 - Thereafter
|
|
|||||
|
|
(in millions)
|
||||||||||||||||||
|
Contractual obligations:
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Long-term debt including current portion
(1)
|
$
|
1,035
|
|
|
$
|
41
|
|
|
$
|
124
|
|
|
$
|
870
|
|
|
$
|
—
|
|
|
Interest payments on long-term debt
(2)
|
186
|
|
|
45
|
|
|
96
|
|
|
45
|
|
|
—
|
|
|||||
|
Operating lease obligations
|
147
|
|
|
39
|
|
|
54
|
|
|
26
|
|
|
28
|
|
|||||
|
Estimated purchase obligations
(3)
|
84
|
|
|
56
|
|
|
28
|
|
|
—
|
|
|
—
|
|
|||||
|
Other long-term liabilities
(4)
|
32
|
|
|
4
|
|
|
7
|
|
|
4
|
|
|
17
|
|
|||||
|
Total contractual obligations
|
$
|
1,484
|
|
|
$
|
185
|
|
|
$
|
309
|
|
|
$
|
945
|
|
|
$
|
45
|
|
|
(1)
|
The amounts presented are based on an anticipated loan repayment schedule. However, we may be required to make certain mandatory prepayments based on our level of cash flow generation and we also have the option to prepay loan principal amounts at any time.
|
|
(2)
|
Amounts include an estimate of future variable interest payments on the Term Loan Facilities based on scheduled outstanding principal amounts, current applicable margin and projected 1- and 3-month LIBOR as of
February 2, 2018
. The amounts presented in this table exclude the effects of interest rate swaps used to hedge against changes in 1- and 3-month LIBOR.
|
|
(3)
|
Includes estimated obligations to transfer funds under legally enforceable agreements for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices. Excludes purchase orders for services or products to be delivered pursuant to U.S. government contracts in which we have full recourse under normal contract termination clauses. In addition, includes $29 million in payments in fiscal 2019 relating to long-lead time materials from various vendors that will be necessary to complete the low-rate initial production (LRIP) phase of our Assault Amphibious Vehicle contract with the United States Marine Corps. As of
February 2, 2018
, we had not yet been fully awarded the LRIP phase, however, we believe it is probable that we will receive the award. In order to meet our anticipated commitments for the LRIP phase, and to maximize volume discounts with our vendors, we committed to purchasing these materials. If we do not receive the award for the LRIP phase we may not be able to recover all of the costs associated with these orders, which would adversely affect our future profitability. In fiscal 2018 we made $5 million in payments relating to these materials for the LRIP phase, bringing the total cost of these orders to $34 million.
|
|
(4)
|
Other long-term liabilities primarily consist of liabilities associated with deferred compensation plan obligations, and liabilities for unrecognized tax benefits. Deferred compensation plan obligations have been allocated to fiscal years based on participants’ payment elections on retirement and estimated retirement ages, but is subject to acceleration on participants’ termination of employment prior to retirement. Liabilities for unrecognized tax benefits are allocated to the fiscal years in which the statute of limitations is currently expected to expire.
|
|
Name of officer
|
Age
|
|
Position(s) with the Company and prior business experience
|
|
|
|
|
|
|
Nazzic S. Keene
|
57
|
|
Chief Operating Officer (COO) since June 2017. Prior to this role Ms. Keene served as Sector President, Global Markets and Missions from September 2013 to June 2017. Ms. Keene served as former Parent’s Senior Vice President for Corporate Strategy and Planning from August 2012 to September 2013. Prior to joining us, Ms. Keene was the Senior Vice President and General Manager for U.S. Enterprise Markets at CGI Group, Inc. from 2004.
|
|
|
|
|
|
|
Steven G. Mahon
|
56
|
|
General Counsel and Corporate Secretary since November 2015. Mr. Mahon previously served as General Counsel, Chief Compliance Officer and Corporate Secretary at MTS Systems Corporation (MTS) from October 2011 to November 2015. Prior to MTS, Mr. Mahon was Assistant General Counsel for Alliant Techsystems Inc. and is a retired Colonel from the U.S. Army where he served in the U.S. Judge Advocate’s General’s Corps, practicing law in a variety of roles on active duty and in the U.S. Army Reserve.
|
|
|
|
|
|
|
Charles A. Mathis
|
58
|
|
Chief Financial Officer since November 2016. Mr. Mathis previously served as CFO at ScanSource Inc., a global public company focused on technology services and products, since 2012. Prior to ScanSource, Mathis was CFO from 2008 to 2012 for Force Protection Inc., based in South Carolina, where he led strategic and operational improvements of the global defense company. He was also the CFO for Fort Worth-based EFW, Inc., the U.S.-based subsidiary of the Israeli defense contractor, Elbit Systems from 2006 to 2008.
|
|
|
|
|
|
|
Anthony J. Moraco
|
58
|
|
Chief Executive Officer since September 2013. Mr. Moraco previously served as the President for the Government Solutions Group of former Parent from February 2013 to September 2013. Mr. Moraco also held positions as Group President of former Parent’s Intelligence, Surveillance and Reconnaissance organization from March 2012 to February 2013, Executive Vice President for Operations and Performance Excellence from August 2010 to March 2012, and Business Unit General Manager and other positions for the Space and Geospatial Intelligence business unit from February 2006 to August 2010. Prior to joining us in 2006, Mr. Moraco worked for The Boeing Company from 2000 to 2006 where he served as the Deputy General Manager of Mission Systems in the Space and Intelligence Systems organization as well as the Director of Homeland Security Technology Integration.
|
|
|
|
|
|
|
Karen A. Wheeler
|
48
|
|
Chief Human Resources Officer since February 2017. Prior to this role, Ms. Wheeler served as Chief Procurement Officer from July 2013 to February 2017. Ms. Wheeler has more than 20 years of experience at SAIC, where she held many key contracts and procurement director positions supporting numerous business areas.
|
|
Equity Compensation Plan Information
|
|||||||||
|
Plan Category
|
Number of securities to be issued upon exercise of outstanding options, warrants and rights
(1)
|
|
|
Weighted-average exercise price of outstanding
options, warrants
and rights
(2)
|
|
|
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
(3)
|
|
|
|
|
(a)
|
|
(b)
|
|
(c)
|
||||
|
Equity compensation plans approved by security holders
|
2,705,306
|
|
|
$
|
43.07
|
|
|
6,124,177
|
|
|
Equity compensation plans not approved by security holders
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
Total
|
2,705,306
|
|
|
|
|
6,124,177
|
|
||
|
(1)
|
This amount includes 1,454,993 stock options outstanding and 1,250,313 shares issuable for other stock-based awards under the 2013 Equity Incentive Plan. This amount does not include shares to be issued pursuant to purchase rights under the 2013 Employee Stock Purchase Plan.
|
|
(2)
|
Does not include shares to be issued for stock-based awards, other than stock options, which will not require any payment upon issuance of those shares.
|
|
(3)
|
Includes 3,082,007 shares of our common stock available for issuance under the 2013 Employee Stock Purchase Plan (ESPP). The maximum number of shares initially available for issuance under the ESPP was 1 million. The ESPP provides for an automatic increase to the share reserve on the first day of each fiscal year beginning on February 1, 2014 in an amount equal to the lesser of (i) 1 million shares, (ii) two percent of the number of shares of our common stock outstanding on the last day of the immediately preceding fiscal year or (iii) a number determined by the Compensation Committee of the Board of Directors. The amount authorized for issuance under the ESPP increased 500,000, 916,198 and 973,477 during fiscal
2017
,
2016
and 2015 respectively. There was no increase to the amount authorized for issuance under the ESPP during fiscal 2018. In addition, this includes 3,042,170 shares of our common stock available for issuance under the 2013 Equity Incentive Plan (EIP). The maximum number of shares initially available for issuance under the EIP was 5.7 million, which was increased by 2.8 million per the amended and restated 2013 Equity Incentive Plan, adopted June 4, 2014, amounting to a total authorized for issuance of 8.5 million. We expect that the number of shares actually issued under the EIP will be significantly less than the number of total awards outstanding under the plan because (a) a net option exercise results in a smaller portion of the number of award shares being issued when a participant uses award shares, rather than cash, to pay the exercise price, which historically most participants have elected to do, (b) most participants historically have elected to let the Company retain award shares to pay for taxes due on the exercise of options and all participants are required to use award shares to pay for taxes upon the vesting of restricted stock or restricted stock units, (c) some participants may terminate employment with the Company before the vesting of awards resulting in awards being forfeited and (d) some participants may not exercise stock options before the expiration date for a variety of reasons, including if the exercise price exceeds the then current market price of shares.
|
|
(a)
|
Documents filed as part of the report
|
|
Science Applications International Corporation
|
||
|
|
|
|
|
By
|
/s/ Charles A. Mathis
|
|
|
|
|
|
|
|
Charles A. Mathis
Chief Financial Officer
|
|
|
Signature
|
|
Title
|
|
Date
|
|
/s/ Anthony J. Moraco
|
|
Principal Executive Officer and Director
|
|
March 29, 2018
|
|
Anthony J. Moraco
|
|
|
||
|
|
|
|
|
|
|
/s/ Charles A. Mathis
|
|
Principal Financial Officer and
Principal Accounting Officer
|
|
March 29, 2018
|
|
Charles A. Mathis
|
|
|
||
|
|
|
|
|
|
|
/s/ Edward J. Sanderson, Jr.
|
|
Chairman of the Board
|
|
March 29, 2018
|
|
Edward J. Sanderson, Jr.
|
|
|
||
|
|
|
|
|
|
|
/s/ Robert A. Bedingfield
|
|
Director
|
|
March 29, 2018
|
|
Robert A. Bedingfield
|
|
|
||
|
|
|
|
|
|
|
/s/ Deborah B. Dunie
|
|
Director
|
|
March 29, 2018
|
|
Deborah B. Dunie
|
|
|
||
|
|
|
|
|
|
|
/s/ John J. Hamre
|
|
Director
|
|
March 29, 2018
|
|
John J. Hamre
|
|
|
||
|
|
|
|
|
|
|
/s/ Mark J. Johnson
|
|
Director
|
|
March 29, 2018
|
|
Mark J. Johnson
|
|
|
||
|
|
|
|
|
|
|
/s/ Timothy J. Mayopoulos
|
|
Director
|
|
March 29, 2018
|
|
Timothy J. Mayopoulos
|
|
|
||
|
|
|
|
|
|
|
/s/ Donna S. Morea
|
|
Director
|
|
March 29, 2018
|
|
Donna S. Morea
|
|
|
||
|
|
|
|
|
|
|
/s/ Steven R. Shane
|
|
Director
|
|
March 29, 2018
|
|
Steven R. Shane
|
|
|
||
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
CONSOLIDATED FINANCIAL STATEMENTS
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
|
|
|
Year Ended
|
||||||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|||
|
|
(in millions, except per share amounts)
|
||||||||||
|
Revenues
|
$
|
4,454
|
|
|
$
|
4,442
|
|
|
$
|
4,315
|
|
|
Cost of revenues
|
4,043
|
|
|
4,003
|
|
|
3,904
|
|
|||
|
Selling, general and administrative expenses
|
155
|
|
|
176
|
|
|
184
|
|
|||
|
Operating income
|
256
|
|
|
263
|
|
|
227
|
|
|||
|
Interest expense
|
44
|
|
|
52
|
|
|
44
|
|
|||
|
Other (income) expense, net
|
(2
|
)
|
|
(1
|
)
|
|
—
|
|
|||
|
Income before income taxes
|
214
|
|
|
212
|
|
|
183
|
|
|||
|
Provision for income taxes (Note 8)
|
(35
|
)
|
|
(69
|
)
|
|
(66
|
)
|
|||
|
Net income
|
$
|
179
|
|
|
$
|
143
|
|
|
$
|
117
|
|
|
Other comprehensive income (loss):
|
|
|
|
|
|
||||||
|
Other comprehensive income (loss), pre-tax
|
8
|
|
|
11
|
|
|
(6
|
)
|
|||
|
Income tax (expense) benefit
|
(3
|
)
|
|
(4
|
)
|
|
2
|
|
|||
|
Total other comprehensive income (loss), net of tax (Note 11)
|
5
|
|
|
7
|
|
|
(4
|
)
|
|||
|
Comprehensive income
|
$
|
184
|
|
|
$
|
150
|
|
|
$
|
113
|
|
|
Earnings per share (Note 2):
|
|
|
|
|
|
||||||
|
Basic
|
$
|
4.13
|
|
|
$
|
3.21
|
|
|
$
|
2.55
|
|
|
Diluted
|
$
|
4.02
|
|
|
$
|
3.12
|
|
|
$
|
2.47
|
|
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
||
|
|
(in millions)
|
||||||
|
ASSETS
|
|
|
|
||||
|
Current assets:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
144
|
|
|
$
|
210
|
|
|
Receivables:
|
|
|
|
||||
|
Billed and billable receivables
|
510
|
|
|
419
|
|
||
|
Unbillable receivables
|
154
|
|
|
112
|
|
||
|
Contract retentions
|
11
|
|
|
10
|
|
||
|
Allowance for doubtful accounts
|
(1
|
)
|
|
(2
|
)
|
||
|
Receivables, net
|
674
|
|
|
539
|
|
||
|
Inventories, net
|
68
|
|
|
71
|
|
||
|
Prepaid expenses
|
35
|
|
|
27
|
|
||
|
Other current assets
|
29
|
|
|
54
|
|
||
|
Total current assets
|
950
|
|
|
901
|
|
||
|
Goodwill (Note 4)
|
863
|
|
|
863
|
|
||
|
Intangible assets, net (Note 4)
|
179
|
|
|
200
|
|
||
|
Property, plant, and equipment, net (Note 5)
|
61
|
|
|
60
|
|
||
|
Other assets
|
20
|
|
|
18
|
|
||
|
Total assets
|
$
|
2,073
|
|
|
$
|
2,042
|
|
|
LIABILITIES AND EQUITY
|
|
|
|
||||
|
Current liabilities:
|
|
|
|
||||
|
Accounts payable
|
$
|
397
|
|
|
$
|
329
|
|
|
Accrued payroll and other employee benefits
|
69
|
|
|
76
|
|
||
|
Accrued vacation
|
81
|
|
|
82
|
|
||
|
Other accrued liabilities
|
107
|
|
|
111
|
|
||
|
Long-term debt, current portion (Note 9)
|
41
|
|
|
25
|
|
||
|
Total current liabilities
|
695
|
|
|
623
|
|
||
|
Long-term debt, net of current portion (Note 9)
|
983
|
|
|
1,022
|
|
||
|
Deferred income taxes
|
23
|
|
|
10
|
|
||
|
Other long-term liabilities
|
45
|
|
|
38
|
|
||
|
Commitments and contingencies (Note 14)
|
|
|
|
||||
|
Equity:
|
|
|
|
||||
|
Common stock, $.0001 par value, 1 billion shares authorized, 43 million shares and 44 million shares issued and outstanding as of February 2, 2018 and February 3, 2017, respectively
|
—
|
|
|
—
|
|
||
|
Additional paid-in capital
|
—
|
|
|
91
|
|
||
|
Retained earnings
|
323
|
|
|
260
|
|
||
|
Accumulated other comprehensive income (loss) (Note 11)
|
4
|
|
|
(2
|
)
|
||
|
Total equity
|
327
|
|
|
349
|
|
||
|
Total liabilities and equity
|
$
|
2,073
|
|
|
$
|
2,042
|
|
|
|
Shares of
common stock
|
|
|
Additional
paid-in
capital
|
|
|
Retained
earnings
|
|
|
Accumulated
other
comprehensive
income (loss)
|
|
|
Total
|
|
||||
|
|
(in millions)
|
|||||||||||||||||
|
Balance at January 30, 2015
|
46
|
|
|
$
|
234
|
|
|
$
|
116
|
|
|
$
|
(5
|
)
|
|
$
|
345
|
|
|
Net income
|
—
|
|
|
—
|
|
|
117
|
|
|
—
|
|
|
117
|
|
||||
|
Issuances of stock
|
—
|
|
|
7
|
|
|
—
|
|
|
—
|
|
|
7
|
|
||||
|
Other comprehensive loss, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
(4
|
)
|
|
(4
|
)
|
||||
|
Cash dividends of $1.21 per share
|
—
|
|
|
—
|
|
|
(59
|
)
|
|
—
|
|
|
(59
|
)
|
||||
|
Stock-based compensation
|
—
|
|
|
25
|
|
|
—
|
|
|
—
|
|
|
25
|
|
||||
|
Income tax benefits from stock-based compensation
|
—
|
|
|
10
|
|
|
—
|
|
|
—
|
|
|
10
|
|
||||
|
Repurchases of stock
|
(1
|
)
|
|
(61
|
)
|
|
—
|
|
|
—
|
|
|
(61
|
)
|
||||
|
Balance at January 29, 2016
|
45
|
|
|
215
|
|
|
174
|
|
|
(9
|
)
|
|
380
|
|
||||
|
Net income
|
—
|
|
|
—
|
|
|
143
|
|
|
—
|
|
|
143
|
|
||||
|
Issuances of stock
|
1
|
|
|
8
|
|
|
—
|
|
|
—
|
|
|
8
|
|
||||
|
Other comprehensive income, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
7
|
|
|
7
|
|
||||
|
Cash dividends of $1.24 per share
|
—
|
|
|
—
|
|
|
(57
|
)
|
|
—
|
|
|
(57
|
)
|
||||
|
Stock-based compensation
|
—
|
|
|
6
|
|
|
—
|
|
|
—
|
|
|
6
|
|
||||
|
Income tax benefits from stock-based compensation
|
—
|
|
|
18
|
|
|
—
|
|
|
—
|
|
|
18
|
|
||||
|
Repurchases of stock
|
(2
|
)
|
|
(156
|
)
|
|
—
|
|
|
—
|
|
|
(156
|
)
|
||||
|
Balance at February 3, 2017
|
44
|
|
|
91
|
|
|
260
|
|
|
(2
|
)
|
|
349
|
|
||||
|
Net income
|
—
|
|
|
—
|
|
|
179
|
|
|
—
|
|
|
179
|
|
||||
|
Issuances of stock
|
1
|
|
|
8
|
|
|
—
|
|
|
—
|
|
|
8
|
|
||||
|
Other comprehensive income, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
5
|
|
|
5
|
|
||||
|
Reclassification of AOCI due to the Tax Act
(1)
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
1
|
|
|
—
|
|
||||
|
Cash dividends of $1.24 per share
|
—
|
|
|
—
|
|
|
(55
|
)
|
|
—
|
|
|
(55
|
)
|
||||
|
Stock-based compensation
|
—
|
|
|
(4
|
)
|
|
—
|
|
|
—
|
|
|
(4
|
)
|
||||
|
Repurchases of stock
|
(2
|
)
|
|
(95
|
)
|
|
(60
|
)
|
|
—
|
|
|
(155
|
)
|
||||
|
Balance at February 2, 2018
|
43
|
|
|
$
|
—
|
|
|
$
|
323
|
|
|
$
|
4
|
|
|
$
|
327
|
|
|
(1)
|
Impact from the adoption of ASU 2018-02 as discussed in Note 1 and Note 11.
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
|
|
|
Year Ended
|
||||||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|||
|
|
(in millions)
|
||||||||||
|
Cash flows from operating activities:
|
|
|
|
|
|
||||||
|
Net income
|
$
|
179
|
|
|
$
|
143
|
|
|
$
|
117
|
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
||||||
|
Depreciation and amortization
|
46
|
|
|
53
|
|
|
62
|
|
|||
|
Deferred income taxes
|
13
|
|
|
(2
|
)
|
|
3
|
|
|||
|
Stock-based compensation expense
|
27
|
|
|
31
|
|
|
33
|
|
|||
|
Excess tax benefits from stock-based compensation
|
—
|
|
|
(18
|
)
|
|
(10
|
)
|
|||
|
Loss on disposal of property, plant, and equipment
|
—
|
|
|
1
|
|
|
1
|
|
|||
|
Loss on extinguishment of debt
|
—
|
|
|
2
|
|
|
—
|
|
|||
|
Increase (decrease) resulting from changes in operating assets and liabilities net of the effect of the acquisition:
|
|
|
|
|
|
||||||
|
Receivables
|
(135
|
)
|
|
96
|
|
|
(5
|
)
|
|||
|
Inventory, prepaid expenses and other current assets
|
19
|
|
|
(36
|
)
|
|
(11
|
)
|
|||
|
Other assets
|
2
|
|
|
—
|
|
|
—
|
|
|||
|
Accounts payable and accrued liabilities
|
68
|
|
|
24
|
|
|
44
|
|
|||
|
Accrued payroll and employee benefits
|
(8
|
)
|
|
(26
|
)
|
|
(4
|
)
|
|||
|
Other long-term liabilities
|
6
|
|
|
5
|
|
|
(4
|
)
|
|||
|
Net cash provided by operating activities
|
217
|
|
|
273
|
|
|
226
|
|
|||
|
Cash flows from investing activities:
|
|
|
|
|
|
||||||
|
Expenditures for property, plant, and equipment
|
(22
|
)
|
|
(15
|
)
|
|
(20
|
)
|
|||
|
Asset acquisition
|
—
|
|
|
(2
|
)
|
|
—
|
|
|||
|
Cash paid for acquisition, net of cash acquired
|
—
|
|
|
—
|
|
|
(764
|
)
|
|||
|
Net cash used in investing activities
|
(22
|
)
|
|
(17
|
)
|
|
(784
|
)
|
|||
|
Cash flows from financing activities:
|
|
|
|
|
|
||||||
|
Dividend payments to stockholders
|
(54
|
)
|
|
(54
|
)
|
|
(55
|
)
|
|||
|
Principal payments on borrowings
|
(50
|
)
|
|
(236
|
)
|
|
(72
|
)
|
|||
|
Issuances of stock
|
6
|
|
|
5
|
|
|
4
|
|
|||
|
Stock repurchased and retired or withheld for taxes on equity awards
|
(186
|
)
|
|
(180
|
)
|
|
(69
|
)
|
|||
|
Excess tax benefits from stock-based compensation
|
—
|
|
|
18
|
|
|
10
|
|
|||
|
Disbursements for obligations assumed from Scitor acquisition
|
(2
|
)
|
|
(7
|
)
|
|
(5
|
)
|
|||
|
Proceeds from borrowings
|
25
|
|
|
209
|
|
|
670
|
|
|||
|
Deferred financing costs
|
—
|
|
|
(2
|
)
|
|
(17
|
)
|
|||
|
Net cash (used in) provided by financing activities
|
(261
|
)
|
|
(247
|
)
|
|
466
|
|
|||
|
Net (decrease) increase in cash, cash equivalents and restricted cash
|
(66
|
)
|
|
9
|
|
|
(92
|
)
|
|||
|
Cash, cash equivalents and restricted cash at beginning of period
|
218
|
|
|
209
|
|
|
301
|
|
|||
|
Cash, cash equivalents and restricted cash at end of period (Note 1)
|
$
|
152
|
|
|
$
|
218
|
|
|
$
|
209
|
|
|
|
|
|
|
|
|
||||||
|
Supplementary cash flow disclosure:
|
|
|
|
|
|
||||||
|
Cash paid for interest
|
$
|
41
|
|
|
$
|
48
|
|
|
$
|
36
|
|
|
Cash paid for income taxes
|
$
|
31
|
|
|
$
|
46
|
|
|
$
|
53
|
|
|
|
|
|
|
|
|
||||||
|
Non-cash investing and financing activities:
|
|
|
|
|
|
||||||
|
(Decrease) increase in accrued plan share repurchases
|
$
|
(1
|
)
|
|
$
|
—
|
|
|
$
|
2
|
|
|
Increase (decrease) in accrued plant, property, and equipment
|
$
|
2
|
|
|
$
|
(1
|
)
|
|
$
|
(2
|
)
|
|
Increase in accrued cash dividend equivalents
|
$
|
—
|
|
|
$
|
1
|
|
|
$
|
1
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Year Ended February 3, 2017
|
|||||||||||
|
|
|
As Reported
|
|
Adjustment
|
|
As Restated
|
||||||
|
|
(in millions, except per share amounts)
|
|||||||||||
|
Revenues
|
|
$
|
4,450
|
|
|
$
|
(8
|
)
|
|
$
|
4,442
|
|
|
Operating income
|
|
271
|
|
|
(8
|
)
|
|
263
|
|
|||
|
Income before taxes
|
|
220
|
|
|
(8
|
)
|
|
212
|
|
|||
|
Provision for income taxes
|
|
(72
|
)
|
|
3
|
|
|
(69
|
)
|
|||
|
Net income
|
|
148
|
|
|
(5
|
)
|
|
143
|
|
|||
|
Comprehensive income
|
|
$
|
155
|
|
|
$
|
(5
|
)
|
|
$
|
150
|
|
|
|
|
|
|
|
|
|
||||||
|
Earnings per share (Note 2):
|
|
|
|
|
|
|
||||||
|
Basic
|
|
$
|
3.33
|
|
|
$
|
(0.12
|
)
|
|
$
|
3.21
|
|
|
Diluted
|
|
$
|
3.22
|
|
|
$
|
(0.10
|
)
|
|
$
|
3.12
|
|
|
|
|
|
|
|
|
|
||||||
|
|
February 3, 2017
|
|||||||||||
|
|
|
As Reported
|
|
Adjustment
|
|
As Restated
|
||||||
|
|
(in millions)
|
|||||||||||
|
Other accrued liabilities
|
|
$
|
103
|
|
|
$
|
8
|
|
|
$
|
111
|
|
|
Total current liabilities
|
|
615
|
|
|
8
|
|
|
623
|
|
|||
|
Deferred income taxes
|
|
13
|
|
|
(3
|
)
|
|
10
|
|
|||
|
Retained earnings
|
|
265
|
|
|
(5
|
)
|
|
260
|
|
|||
|
Total equity
|
|
354
|
|
|
(5
|
)
|
|
349
|
|
|||
|
Total liabilities and equity
|
|
$
|
2,042
|
|
|
$
|
—
|
|
|
$
|
2,042
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Fiscal 2018
|
|
|
Fiscal 2017
|
|
|
Fiscal 2016
|
|
|
|
(weeks)
|
|||||||
|
First Quarter
|
13
|
|
|
14
|
|
|
13
|
|
|
Second Quarter
|
13
|
|
|
13
|
|
|
13
|
|
|
Third Quarter
|
13
|
|
|
13
|
|
|
13
|
|
|
Fourth Quarter
|
13
|
|
|
13
|
|
|
13
|
|
|
Fiscal Year
|
52
|
|
|
53
|
|
|
52
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Year Ended
|
||||||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|||
|
|
(in millions, except per share amounts)
|
||||||||||
|
Favorable adjustments
|
$
|
27
|
|
|
$
|
42
|
|
|
$
|
29
|
|
|
Unfavorable adjustments
|
(30
|
)
|
|
(20
|
)
|
|
(16
|
)
|
|||
|
Net (unfavorable) favorable adjustments
|
(3
|
)
|
|
22
|
|
|
13
|
|
|||
|
Income tax effect
|
1
|
|
|
(7
|
)
|
|
(5
|
)
|
|||
|
Net (unfavorable) favorable adjustments, after tax
|
(2
|
)
|
|
15
|
|
|
8
|
|
|||
|
Basic EPS impact
|
$
|
(0.05
|
)
|
|
$
|
0.34
|
|
|
$
|
0.17
|
|
|
Diluted EPS impact
|
$
|
(0.04
|
)
|
|
$
|
0.33
|
|
|
$
|
0.17
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
February 2, 2018
|
|
|
February 3, 2017
|
|
||
|
|
(in millions)
|
||||||
|
Cash and cash equivalents
|
$
|
144
|
|
|
$
|
210
|
|
|
Restricted cash included in other current assets
|
—
|
|
|
1
|
|
||
|
Restricted cash included in other assets
|
8
|
|
|
7
|
|
||
|
Cash, cash equivalents and restricted cash
|
$
|
152
|
|
|
$
|
218
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Year Ended
|
|||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|
|
(in millions)
|
|||||||
|
Basic weighted-average number of shares outstanding
|
43.3
|
|
|
44.5
|
|
|
45.8
|
|
|
Dilutive common share equivalents - stock options and other stock-based awards
|
1.2
|
|
|
1.4
|
|
|
1.6
|
|
|
Diluted weighted-average number of shares outstanding
|
44.5
|
|
|
45.9
|
|
|
47.4
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Year Ended
|
|||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|
|
(in millions)
|
|||||||
|
Antidilutive stock options excluded
|
0.2
|
|
|
0.2
|
|
|
0.3
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Year Ended
|
||
|
|
January 29,
2016 |
|
|
|
(in millions, except per share amounts)
|
|
||
|
Total revenues
|
$
|
4,463
|
|
|
Net income
|
$
|
143
|
|
|
Earnings per share:
|
|
||
|
Basic
|
$
|
3.12
|
|
|
Diluted
|
$
|
3.02
|
|
|
|
February 2, 2018
|
|
February 3, 2017
|
||||||||||||||||||||
|
|
Gross carrying value
|
|
|
Accumulated amortization
|
|
|
Net carrying value
|
|
|
Gross carrying value
|
|
|
Accumulated amortization
|
|
|
Net carrying value
|
|
||||||
|
|
(in millions)
|
||||||||||||||||||||||
|
Customer relationships
|
$
|
234
|
|
|
$
|
(55
|
)
|
|
$
|
179
|
|
|
$
|
240
|
|
|
$
|
(40
|
)
|
|
$
|
200
|
|
|
Fiscal Year Ending
|
(in millions)
|
|
|
|
2019
|
$
|
20
|
|
|
2020
|
20
|
|
|
|
2021
|
20
|
|
|
|
2022
|
20
|
|
|
|
2023
|
20
|
|
|
|
Thereafter
|
79
|
|
|
|
Total
|
$
|
179
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Depreciation or
amortization method
|
|
Estimated useful lives (in years)
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
||
|
|
|
|
|
|
(in millions)
|
||||||
|
Computer equipment
|
Straight-line or
declining balance |
|
3-10
|
|
$
|
75
|
|
|
$
|
67
|
|
|
Capitalized software and software licenses
|
Straight-line or
declining balance |
|
3-10
|
|
58
|
|
|
55
|
|
||
|
Leasehold improvements
|
Straight-line
|
|
Shorter of lease term or 10
|
|
53
|
|
|
46
|
|
||
|
Office furniture and fixtures
|
Straight-line or
declining balance |
|
3-10
|
|
11
|
|
|
11
|
|
||
|
Buildings and improvements
|
Straight-line
|
|
40
|
|
7
|
|
|
7
|
|
||
|
Property, plant, and equipment
|
|
|
|
|
204
|
|
|
186
|
|
||
|
Accumulated depreciation and amortization
|
|
|
|
|
(143
|
)
|
|
(126
|
)
|
||
|
Property, plant, and equipment, net
|
|
|
|
|
$
|
61
|
|
|
$
|
60
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Year Ended
|
||||||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|||
|
|
(in millions)
|
||||||||||
|
Stock-based compensation expense:
|
|
|
|
|
|
||||||
|
Stock options
|
$
|
3
|
|
|
$
|
4
|
|
|
$
|
4
|
|
|
Vesting stock awards
|
21
|
|
|
24
|
|
|
25
|
|
|||
|
Performance share awards
|
3
|
|
|
3
|
|
|
4
|
|
|||
|
Total stock-based compensation expense
|
$
|
27
|
|
|
$
|
31
|
|
|
$
|
33
|
|
|
Tax benefits recognized from stock-based compensation
|
$
|
32
|
|
|
$
|
12
|
|
|
$
|
13
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Shares of stocks under stock options
|
|
|
Weighted average exercise price
|
|
|
Weighted average remaining contractual term
|
|
Aggregate intrinsic value
|
|
||
|
|
(in millions)
|
|
|
|
|
(in years)
|
|
(in millions)
|
|
|||
|
Outstanding at February 3, 2017
|
1.9
|
|
|
$
|
38.57
|
|
|
4.0
|
|
$
|
84
|
|
|
Options granted
|
0.2
|
|
|
73.39
|
|
|
|
|
|
|||
|
Options forfeited or expired
|
(0.1
|
)
|
|
57.90
|
|
|
|
|
|
|||
|
Options exercised
|
(0.6
|
)
|
|
35.12
|
|
|
|
|
|
|||
|
Outstanding at February 2, 2018
|
1.4
|
|
|
$
|
43.07
|
|
|
3.5
|
|
$
|
46
|
|
|
Options exercisable at February 2, 2018
|
1.1
|
|
|
$
|
36.70
|
|
|
2.8
|
|
$
|
41
|
|
|
Vested and expected to vest as of February 2, 2018
|
1.4
|
|
|
$
|
42.90
|
|
|
3.5
|
|
$
|
46
|
|
|
|
Year Ended
|
||||||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|||
|
|
(in millions)
|
||||||||||
|
Cash received from exercises of stock options
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Stock exchanged at fair value upon exercises of stock options
|
$
|
1
|
|
|
$
|
3
|
|
|
$
|
3
|
|
|
Tax benefits from exercises of stock options
|
$
|
8
|
|
|
$
|
8
|
|
|
$
|
3
|
|
|
Total intrinsic value of options exercised
|
$
|
22
|
|
|
$
|
21
|
|
|
$
|
10
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Year Ended
|
||||||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|||
|
Weighted average grant-date fair value
|
$
|
16.34
|
|
|
$
|
10.20
|
|
|
$
|
11.76
|
|
|
Expected term (in years)
|
4.4
|
|
|
4.4
|
|
|
4.5
|
|
|||
|
Expected volatility
|
28.2
|
%
|
|
28.9
|
%
|
|
31.7
|
%
|
|||
|
Risk-free interest rate
|
1.7
|
%
|
|
1.2
|
%
|
|
1.2
|
%
|
|||
|
Dividend yield
|
1.5
|
%
|
|
2.7
|
%
|
|
2.1
|
%
|
|||
|
|
Shares of stock under stock awards
|
|
|
Weighted average grant date fair value
|
|
|
|
|
(in millions)
|
|||||
|
Unvested February 3, 2017
|
1.4
|
|
|
$
|
43.46
|
|
|
Awards granted
|
0.4
|
|
|
72.90
|
|
|
|
Awards forfeited
|
(0.1
|
)
|
|
61.74
|
|
|
|
Awards vested
|
(0.8
|
)
|
|
38.21
|
|
|
|
Unvested February 2, 2018
|
0.9
|
|
|
$
|
59.93
|
|
|
|
Shares of stock under performance shares
|
|
|
Weighted average grant date fair value
|
|
|
|
|
(in millions)
|
|
|
|
||
|
Unvested performance shares at February 3, 2017
|
0.2
|
|
|
$
|
52.73
|
|
|
Performance shares granted
|
0.1
|
|
|
72.91
|
|
|
|
Performance shares forfeited
|
—
|
|
|
—
|
|
|
|
Performance shares vested
|
(0.1
|
)
|
|
52.11
|
|
|
|
Performance shares adjustment
|
—
|
|
|
—
|
|
|
|
Unvested performance shares at February 2, 2018
|
0.2
|
|
|
$
|
62.96
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Year Ended
|
||||||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|||
|
|
(in millions)
|
||||||||||
|
Current:
|
|
|
|
|
|
||||||
|
Federal
|
$
|
3
|
|
|
$
|
59
|
|
|
$
|
51
|
|
|
State
|
2
|
|
|
12
|
|
|
12
|
|
|||
|
Deferred:
|
|
|
|
|
|
||||||
|
Federal
|
26
|
|
|
2
|
|
|
5
|
|
|||
|
State
|
4
|
|
|
(4
|
)
|
|
(2
|
)
|
|||
|
Total
|
$
|
35
|
|
|
$
|
69
|
|
|
$
|
66
|
|
|
|
Year Ended
|
||||||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|||
|
|
(in millions)
|
||||||||||
|
Statutory federal income tax rate
(1)
|
33.7
|
%
|
|
35.0
|
%
|
|
35.0
|
%
|
|||
|
Amount computed at the blended statutory federal income tax rate
|
$
|
72
|
|
|
$
|
74
|
|
|
$
|
64
|
|
|
State income taxes, net of federal tax benefit
|
8
|
|
|
6
|
|
|
6
|
|
|||
|
Research and development credits
|
(3
|
)
|
|
(8
|
)
|
|
(2
|
)
|
|||
|
Federal income tax reduction per the Tax Act
|
(17
|
)
|
|
—
|
|
|
—
|
|
|||
|
Manufacturer's deduction
|
(1
|
)
|
|
(2
|
)
|
|
(4
|
)
|
|||
|
Non-deductible acquisition costs
|
—
|
|
|
—
|
|
|
2
|
|
|||
|
Excess tax benefits for stock-based compensation
|
(22
|
)
|
|
—
|
|
|
—
|
|
|||
|
Work opportunity tax credit
|
(1
|
)
|
|
(1
|
)
|
|
—
|
|
|||
|
Other
|
(1
|
)
|
|
—
|
|
|
—
|
|
|||
|
Total
|
$
|
35
|
|
|
$
|
69
|
|
|
$
|
66
|
|
|
Effective income tax rate
|
16.5
|
%
|
|
32.7
|
%
|
|
36.0
|
%
|
|||
|
(1)
|
The statutory federal income tax rate for fiscal 2018 is a blended rate due to the Tax Act. See Note 1.
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
||
|
|
(in millions)
|
||||||
|
Accrued vacation and bonuses
|
$
|
18
|
|
|
$
|
27
|
|
|
Accrued liabilities
|
3
|
|
|
8
|
|
||
|
Deferred compensation
|
14
|
|
|
22
|
|
||
|
Stock awards
|
9
|
|
|
17
|
|
||
|
Net operating loss carry-forward & tax credits-carry forward
|
12
|
|
|
21
|
|
||
|
Accumulated other comprehensive loss
|
—
|
|
|
1
|
|
||
|
Valuation allowance
|
(1
|
)
|
|
(1
|
)
|
||
|
Total deferred tax assets
|
55
|
|
|
95
|
|
||
|
Deferred revenue
|
(20
|
)
|
|
(28
|
)
|
||
|
Fixed asset basis differences
|
(6
|
)
|
|
(6
|
)
|
||
|
Purchased intangible assets
|
(51
|
)
|
|
(69
|
)
|
||
|
Accumulated other comprehensive income
|
(1
|
)
|
|
—
|
|
||
|
Total deferred tax liabilities
|
(78
|
)
|
|
(103
|
)
|
||
|
Net deferred tax liabilities
|
$
|
(23
|
)
|
|
$
|
(8
|
)
|
|
|
Year Ended
|
||||||||||
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|
January 29,
2016 |
|
|||
|
|
(in millions)
|
||||||||||
|
Unrecognized tax benefits at beginning of the year
|
$
|
5
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Additions for tax positions related to prior years
|
1
|
|
|
2
|
|
|
—
|
|
|||
|
Additions for tax positions related to the current year
|
1
|
|
|
3
|
|
|
—
|
|
|||
|
Unrecognized tax benefits at end of the year
|
$
|
7
|
|
|
$
|
5
|
|
|
$
|
—
|
|
|
Unrecognized tax benefits that, if recognized, would affect the effective income tax rate
|
$
|
7
|
|
|
$
|
5
|
|
|
$
|
—
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
February 2, 2018
|
|
February 3, 2017
|
||||||||||||||||||||||||||
|
|
Stated interest rate
|
|
|
Effective interest rate
|
|
|
Principal
|
|
|
Unamortized Debt Issuance Costs
|
|
|
Net
|
|
|
Principal
|
|
|
Unamortized Debt Issuance Costs
|
|
|
Net
|
|
||||||
|
|
|
|
|
|
(in millions)
|
||||||||||||||||||||||||
|
Term Loan A Facility due August 2021
|
3.88
|
%
|
|
3.99
|
%
|
|
$
|
635
|
|
|
$
|
(2
|
)
|
|
$
|
633
|
|
|
$
|
660
|
|
|
$
|
(2
|
)
|
|
$
|
658
|
|
|
Term Loan B Facility due May 2022
|
3.94
|
%
|
|
4.54
|
%
|
|
400
|
|
|
(9
|
)
|
|
391
|
|
|
400
|
|
|
(11
|
)
|
|
389
|
|
||||||
|
Total long-term debt
|
|
|
|
|
$
|
1,035
|
|
|
$
|
(11
|
)
|
|
$
|
1,024
|
|
|
$
|
1,060
|
|
|
$
|
(13
|
)
|
|
$
|
1,047
|
|
||
|
Less current portion
|
|
|
|
|
41
|
|
|
—
|
|
|
41
|
|
|
25
|
|
|
—
|
|
|
25
|
|
||||||||
|
Total long-term debt, net of current portion
|
|
|
|
|
$
|
994
|
|
|
$
|
(11
|
)
|
|
$
|
983
|
|
|
$
|
1,035
|
|
|
$
|
(13
|
)
|
|
$
|
1,022
|
|
||
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
Fiscal Year Ending
|
Total
|
|
|
|
|
(in millions)
|
|
|
|
2019
|
$
|
41
|
|
|
2020
|
58
|
|
|
|
2021
|
66
|
|
|
|
2022
|
469
|
|
|
|
2023
|
401
|
|
|
|
Total principal payments
|
$
|
1,035
|
|
|
|
|
|
|
|
|
|
|
|
Asset (Liability) Fair Value
(1)
at
|
|||||||||
|
|
Notional Amount at February 2, 2018
|
|
|
Pay Fixed Rate
|
|
|
Receive Variable Rate
|
|
Settlement and Termination
|
|
February 2,
2018 |
|
|
February 3,
2017 |
|
|||
|
|
(in millions)
|
|
|
|
|
|
|
|
(in millions)
|
|||||||||
|
Term loan A interest rate swaps
|
$
|
363
|
|
|
1.41
|
%
|
|
1-month LIBOR
|
|
Monthly through September 26, 2018
|
|
$
|
1
|
|
|
$
|
(1
|
)
|
|
Term loan B interest rate swaps
|
350
|
|
|
1.88
|
%
|
|
3-month LIBOR
(2)
|
|
Quarterly through May 7, 2020
|
|
4
|
|
|
(2
|
)
|
|||
|
Total
|
$
|
713
|
|
|
|
|
|
|
|
|
$
|
5
|
|
|
$
|
(3
|
)
|
|
|
(1)
|
The fair value of the fixed interest rate swaps asset is included in other assets on the consolidated balance sheets. The fair value of the fixed interest rate swaps liability is included in other accrued liabilities on the consolidated balance sheets.
|
|
(2)
|
Subject to a
0.75%
floor.
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
|
|
|
Unrealized Gains (Losses) on Fixed Interest Rate
Swap Cash Flow Hedges
|
||||||||||
|
|
Pre-Tax
Amount
(1)
|
|
|
Income
Tax
(2)
|
|
|
Net
Amount
|
|
|||
|
|
(in millions)
|
||||||||||
|
Balance at February 3, 2017
|
$
|
(3
|
)
|
|
$
|
1
|
|
|
$
|
(2
|
)
|
|
Other comprehensive income before reclassifications
|
5
|
|
|
(2
|
)
|
|
3
|
|
|||
|
Amounts reclassified from accumulated other comprehensive loss
|
3
|
|
|
(1
|
)
|
|
2
|
|
|||
|
Net other comprehensive income
|
8
|
|
|
(3
|
)
|
|
5
|
|
|||
|
Impact of the Tax Act
(3)
|
—
|
|
|
1
|
|
|
1
|
|
|||
|
Balance at February 2, 2018
|
$
|
5
|
|
|
$
|
(1
|
)
|
|
$
|
4
|
|
|
Balance at January 30, 2016
|
$
|
(14
|
)
|
|
$
|
5
|
|
|
$
|
(9
|
)
|
|
Other comprehensive income before reclassifications
|
3
|
|
|
(1
|
)
|
|
2
|
|
|||
|
Amounts reclassified from accumulated other comprehensive loss
|
8
|
|
|
(3
|
)
|
|
5
|
|
|||
|
Net other comprehensive income
|
11
|
|
|
(4
|
)
|
|
7
|
|
|||
|
Balance at February 3, 2017
|
$
|
(3
|
)
|
|
$
|
1
|
|
|
$
|
(2
|
)
|
|
Balance at January 30, 2015
|
$
|
(8
|
)
|
|
$
|
3
|
|
|
$
|
(5
|
)
|
|
Other comprehensive loss before reclassifications
|
(15
|
)
|
|
6
|
|
|
(9
|
)
|
|||
|
Amounts reclassified from accumulated other comprehensive loss
|
9
|
|
|
(4
|
)
|
|
5
|
|
|||
|
Net other comprehensive loss
|
(6
|
)
|
|
2
|
|
|
(4
|
)
|
|||
|
Balance at January 29, 2016
|
$
|
(14
|
)
|
|
$
|
5
|
|
|
$
|
(9
|
)
|
|
(1)
|
The amount reclassified from accumulated other comprehensive income (loss) is included in interest expense.
|
|
(2)
|
The amount reclassified from accumulated other comprehensive income (loss) is included in the provision for income taxes.
|
|
(3)
|
The amount reclassified from accumulated other comprehensive income to retained earnings from the adoption of ASU 2018-02 as discussed in Note 1.
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
Fiscal Year Ending
|
(in millions)
|
|
|
|
2019
|
$
|
39
|
|
|
2020
|
31
|
|
|
|
2021
|
23
|
|
|
|
2022
|
20
|
|
|
|
2023
|
6
|
|
|
|
Thereafter
|
28
|
|
|
|
Total
|
$
|
147
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
First
Quarter
|
|
|
Second
Quarter
|
|
|
Third
Quarter
|
|
|
Fourth
Quarter
|
|
||||
|
|
(in millions, except per share amounts)
|
||||||||||||||
|
Fiscal 2018
|
|
|
|
|
|
|
|
||||||||
|
Revenues
|
$
|
1,103
|
|
|
$
|
1,078
|
|
|
$
|
1,145
|
|
|
$
|
1,128
|
|
|
Operating income
|
63
|
|
|
59
|
|
|
72
|
|
|
62
|
|
||||
|
Net income
|
49
|
|
|
36
|
|
|
43
|
|
|
51
|
|
||||
|
Basic EPS
|
$
|
1.12
|
|
|
$
|
0.83
|
|
|
$
|
0.99
|
|
|
$
|
1.19
|
|
|
Diluted EPS
|
$
|
1.08
|
|
|
$
|
0.80
|
|
|
$
|
0.98
|
|
|
$
|
1.16
|
|
|
Fiscal 2017
(1)
|
|
|
|
|
|
|
|
||||||||
|
Revenues
|
$
|
1,213
|
|
|
$
|
1,093
|
|
|
$
|
1,112
|
|
|
$
|
1,024
|
|
|
Operating income
|
64
|
|
|
68
|
|
|
72
|
|
|
59
|
|
||||
|
Net income
|
31
|
|
|
36
|
|
|
41
|
|
|
35
|
|
||||
|
Basic EPS
|
$
|
0.69
|
|
|
$
|
0.80
|
|
|
$
|
0.93
|
|
|
$
|
0.79
|
|
|
Diluted EPS
|
$
|
0.67
|
|
|
$
|
0.78
|
|
|
$
|
0.90
|
|
|
$
|
0.77
|
|
|
(1)
|
Fiscal 2017 amounts have been restated to adjust for the impacts from the correction of fiscal 2017 revenues as described and reconciled in Note 1. This correction has the impact of reducing each quarter's revenues in fiscal 2017 by
$2 million
.
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
EXHIBIT INDEX
|
|
Exhibit
Number
|
Description of Exhibit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
EXHIBIT INDEX
|
|
Exhibit
Number
|
Description of Exhibit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
EXHIBIT INDEX
|
|
Exhibit
Number
|
Description of Exhibit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101
|
Interactive Data File.
|
|
*
|
Compensation Plans and Arrangements
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|